Trial Details

COMPLETED
Basic Information
Clinical ID c48
Identifier NCT07273760
Trial Title VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis (UC)|Crohn Disease (CD)|Inflammatory Bowel Disease (IBD)
Interventions DRUG: Vedolizumab
Participant Information
Sponsor AryoGen Pharmed Co.
City Fars
Country/Region Iran
Enrollment Criteria
Sex Requirement ALL
Age Requirement CHILD, ADULT, OLDER_ADULT
Study Design
Study Type OBSERVATIONAL
Phase NULL
Time Information
Start Date 2023-07-16
Primary Completion Date 2025-09-30
Completion Date 2025-10-05